Pelger–Huët anomaly
(Redirected from Pelger–Huet anomaly)
Genetic blood disorder with abnormal neutrophil nuclei
Pelger–Huët anomaly | |
---|---|
![]() | |
Synonyms | PHA, Pelger anomaly, Huët anomaly |
Pronounce | nl |
Field | N/A |
Symptoms | N/A |
Complications | Generally benign in heterozygotes; potential immune dysfunction in homozygotes |
Onset | Congenital |
Duration | Lifelong |
Types | Congenital Pelger–Huët anomaly, Pseudo–Pelger–Huët anomaly |
Causes | Mutation in the lamin B receptor (LBR) gene |
Risks | Family history of the disorder |
Diagnosis | Peripheral blood smear, genetic testing |
Differential diagnosis | Pseudo–Pelger–Huët anomaly, Myelodysplastic syndrome |
Prevention | None |
Treatment | Supportive; no specific treatment needed for congenital form |
Medication | None |
Prognosis | Excellent for heterozygous congenital form |
Frequency | Rare |
Deaths | None (for congenital form) |

Pelger–Huët anomaly (PHA) is a rare, benign genetic disorder affecting the white blood cells, primarily the neutrophils and eosinophils. It is classified as a type of laminopathy and results from mutations in the lamin B receptor (LBR) gene. The hallmark of PHA is the abnormal shape of the cell nucleus, which typically appears as bilobed, peanut-shaped, or dumbbell-shaped, rather than the usual multi-lobed (trilobed) configuration.
History[edit | edit source]
The condition was first described in 1928 by Dutch hematologist Karel Pelger, who noted the distinctive appearance of neutrophil nuclei. In 1931, Gauthier Jean Huët, a Dutch pediatrician, recognized the hereditary nature of this anomaly, leading to the eponymous naming of the disorder.
Pathophysiology[edit | edit source]
The lamin B receptor gene, located on chromosome 1q42.1, encodes an inner nuclear membrane protein involved in chromatin organization and nuclear envelope stability. Mutations in this gene disrupt the terminal differentiation of neutrophils, leading to characteristic nuclear hyposegmentation.
Genetics[edit | edit source]
Pelger–Huët anomaly is inherited in an autosomal dominant pattern:
- Heterozygotes exhibit typical bilobed or hyposegmented nuclei in neutrophils but are clinically asymptomatic.
- Homozygotes may present with more pronounced nuclear abnormalities and can have mild hematological dysfunction, including altered neutrophil mobility and impaired chemotaxis.
Types[edit | edit source]
Congenital Pelger–Huët anomaly[edit | edit source]
The congenital form is inherited and considered benign. It is not associated with illness or increased susceptibility to infection in heterozygous carriers. The neutrophils in these individuals retain normal function despite abnormal nuclear morphology.
Pseudo–Pelger–Huët anomaly[edit | edit source]
This is an acquired form and may occur in association with:
- Myelodysplastic syndrome (MDS)
- Acute myeloid leukemia (AML)
- Chronic myelogenous leukemia (CML)
- HIV/AIDS
- After exposure to certain medications (e.g., chemotherapeutic agents, immunosuppressants)
This form can be an indicator of serious underlying pathology and requires further investigation.
Diagnosis[edit | edit source]
Diagnosis of Pelger–Huët anomaly includes:
- **Peripheral blood smear**: Neutrophils with bilobed or round nuclei and dense clumped chromatin.
- **Genetic testing**: Confirmation of LBR gene mutation if necessary.
- **Family history**: Important to distinguish congenital from acquired forms.
Differential diagnosis[edit | edit source]
- Pseudo–Pelger–Huët anomaly due to underlying hematologic disease
- Neutrophil dysplasia in myelodysplastic syndromes
- Left shift in infection or stress
Clinical significance[edit | edit source]
While Pelger–Huët anomaly is largely benign in congenital form, it is crucial to distinguish it from its pseudo-form to avoid misdiagnosis. Misinterpretation as immature granulocytes can lead to inappropriate clinical management.
Management[edit | edit source]
No treatment is required for the congenital form. Recognition of the anomaly prevents unnecessary diagnostic testing or treatment.
For the acquired (pseudo) form, management involves addressing the underlying disease or discontinuing the causative medication.
See also[edit | edit source]
External links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD